No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology.

Abstract

PURPOSE:

To undertake a new protocol with the goals of improving the chemotherapeutic treatment of pediatric Ewing's sarcoma by introducing ifosfamide, and to widen the indications for surgical resection of Ewing's tumor to obtain better local control and to reduce radiation doses.

PATIENTS AND METHODS:

The French Society of Pediatric Oncology initiated its first cooperative Ewing's sarcoma study in 1978, using a four-drug regimen (cyclophosphamide, dactinomycin, Adriamycin [doxorubicin; Farmitalia Carlo Erba, Rueil-Malmaison, France], and vincristine). Ninety-five patients were included, and, at 5 years, the disease-free survival reached a plateau of 51%. After encouraging responses of recurrent soft tissue or bone sarcomas to ifosfamide, a second study began in 1984 using a new chemotherapy regimen in which cyclophosphamide was replaced by ifosfamide. Sixty-five patients were treated.

RESULTS:

By February 1992, the median follow-up was 5.8 years. The estimated 5-year disease-free survival was 52%. We observed unexpected cardiac toxicity. Three patients experienced acute cardiac failure that was lethal in two cases. The acute toxicity of ifosfamide prompted us to stop the protocol. Retrospectively, the lack of efficacy reinforced our decision.

CONCLUSION:

We conclude that ifosfamide did not improve the outcome of the patients despite the fact that these two treatment regimens were not randomized.

• Authors: O Oberlin, J L Habrand, J M Zucker, M Brunat-Mentigny, M J Terrier-Lacombe, J Dubousset, J C Gentet, C Schmitt, D Ponvert, C Carrié
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 10 Issue 9 Pg. 1407-12 (Sep 1992) ISSN: 0732-183X [Print] United States
• PMID: 1517783 (Publication Type: Journal Article)

Chemical References

• Ifosfamide

Topics

• Bone Neoplasms (drug therapy, radiotherapy, surgery)
• Child
• Combined Modality Therapy
• Female
• Follow-Up Studies
• Humans
• Ifosfamide (adverse effects, therapeutic use)
• Male
• Prognosis
• Recurrence
• Sarcoma, Ewing (drug therapy, radiotherapy, surgery)
• Survival Analysis
• Treatment Outcome